share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
美股sec公告 ·  05/15 16:25
Moomoo AI 已提取核心信息
On May 15, 2024, Panbela Therapeutics, Inc. released its financial results for the first quarter ended March 31, 2024. The company, which is developing treatments for urgent unmet medical needs, announced that the interim data analysis for its ASPIRE trial, targeting metastatic pancreatic ductal adenocarcinoma with ivospemin (SBP-101), is now expected in Q1 2025. This delay is attributed to a lower-than-anticipated event rate, suggesting potential for improved patient survival outcomes. The ASPIRE trial has surpassed 50% enrollment, with full enrollment of approximately 600 patients projected by Q1 2025. Financially, Panbela reported a net loss of approximately $7.1 million, or $2.28 per diluted share, an increase from the previous year's net loss of $5.1 million, or $392.76 per diluted share. This was primarily due to increased research and development expenses associated with the ASPIRE trial. The company also completed a $9.0 million public offering of common stock and warrants, with net proceeds of approximately $8.1 million. Panbela's common stock is quoted on the OTCQB under the symbol 'PBLA'.
On May 15, 2024, Panbela Therapeutics, Inc. released its financial results for the first quarter ended March 31, 2024. The company, which is developing treatments for urgent unmet medical needs, announced that the interim data analysis for its ASPIRE trial, targeting metastatic pancreatic ductal adenocarcinoma with ivospemin (SBP-101), is now expected in Q1 2025. This delay is attributed to a lower-than-anticipated event rate, suggesting potential for improved patient survival outcomes. The ASPIRE trial has surpassed 50% enrollment, with full enrollment of approximately 600 patients projected by Q1 2025. Financially, Panbela reported a net loss of approximately $7.1 million, or $2.28 per diluted share, an increase from the previous year's net loss of $5.1 million, or $392.76 per diluted share. This was primarily due to increased research and development expenses associated with the ASPIRE trial. The company also completed a $9.0 million public offering of common stock and warrants, with net proceeds of approximately $8.1 million. Panbela's common stock is quoted on the OTCQB under the symbol 'PBLA'.
2024年5月15日，Panbela Therapeutics, Inc.发布了截至2024年3月31日的第一季度财务业绩。该公司正在为未满足的紧急医疗需求开发治疗方法，该公司宣布，其针对转移性胰腺导管腺癌的ASPIRE试验（SBP-101）的中期数据分析现预计将于2025年第一季度公布。这种延迟归因于事件发生率低于预期，这表明患者存活率有可能得到改善。ASPIRE试验的入组人数已超过50％，预计到2025年第一季度将有约600名患者入组。财务方面，Panbela报告净亏损约710万美元，摊薄每股亏损2.28美元，较上一年的净亏损510万美元或摊薄后每股亏损392.76美元有所增加。这主要是由于与ASPIRE试验相关的研发费用增加。该公司还完成了900万澳元的普通股和认股权证的公开发行，净收益约为810万美元。Panbela的普通股在OTCQB上市，股票代码为 “PBLA”。
2024年5月15日，Panbela Therapeutics, Inc.发布了截至2024年3月31日的第一季度财务业绩。该公司正在为未满足的紧急医疗需求开发治疗方法，该公司宣布，其针对转移性胰腺导管腺癌的ASPIRE试验（SBP-101）的中期数据分析现预计将于2025年第一季度公布。这种延迟归因于事件发生率低于预期，这表明患者存活率有可能得到改善。ASPIRE试验的入组人数已超过50％，预计到2025年第一季度将有约600名患者入组。财务方面，Panbela报告净亏损约710万美元，摊薄每股亏损2.28美元，较上一年的净亏损510万美元或摊薄后每股亏损392.76美元有所增加。这主要是由于与ASPIRE试验相关的研发费用增加。该公司还完成了900万澳元的普通股和认股权证的公开发行，净收益约为810万美元。Panbela的普通股在OTCQB上市，股票代码为 “PBLA”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息